Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History EBS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics EBS

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield 25.48 %
Consecutive Years 0
Forward Annual Dividend 1.86 USD
Consistent Years 0
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date 01.08.2016

Emergent Biosolutions Inc

EBS
Current price
6.93 USD -0.4 USD (-5.46%)
Last closed 6.99 USD
ISIN US29089Q1058
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange NYSE
Capitalization 376 145 152 USD
Yield for 12 month -38.13 %
1Y
3Y
5Y
10Y
15Y
EBS
21.11.2021 - 28.11.2021

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; Botulism Antitoxin Heptavalent for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Trobigard, an atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland. Address: 300 Professional Drive, Gaithersburg, MD, United States, 20879

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

13.50 USD

P/E Ratio

Dividend Yield

Financials EBS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures EBS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+1 013 600 000 USD

Last Year

+1 049 300 000 USD

Current Quarter

+222 200 000 USD

Last Quarter

+189 300 000 USD

Current Year

+305 200 000 USD

Last Year

+343 900 000 USD

Current Quarter

+133 700 000 USD

Last Quarter

+60 000 000 USD
EBITDA 61 800 000 USD
Operating Margin TTM 22.68 %
Price to Earnings
Return On Assets TTM -1.61 %
PEG Ratio 1.55
Return On Equity TTM -21.63 %
Wall Street Target Price 13.50 USD
Revenue TTM 965 400 000 USD
Book Value 10.14 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -26.00 %
Dividend Yield
Gross Profit TTM 354 000 000 USD
Earnings per share -2.58 USD
Diluted Eps TTM -2.58 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY 600.00 %
Profit Margin -13.63 %

Stock Valuation EBS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 46.30
Enterprise Value Revenue 0.96
Price Sales TTM 0.39
Enterprise Value EBITDA 8.47
Price Book MRQ 0.68

Technical Indicators EBS

For 52 Weeks

4.02 USD 15.10 USD
50 Day MA 6.34 USD
Shares Short Prior Month 7 911 368
200 Day MA 7.69 USD
Short Ratio 7.18
Shares Short 7 991 534
Short Percent 14.87 %